Advancements in Medical Research

🔥 Patients in complete remission in autoimmune disease via CAR-T Nature reports that CAR-T cell therapy, originally built to fight cancer, is now sending severe autoimmune diseases into remission. Not partial remission. Full disappearance of symptoms. Patients who were chronically ill now have no detectable autoantibodies and feel “cured”. As a neuroscientist working in translational science, I find this incredibly significant. The idea that a single immune reset can silence diseases like lupus, rheumatoid arthritis, myasthenia gravis or ulcerative colitis was unthinkable only a few years ago. Now we see patients returning to work, stopping medications and living without symptoms for months. What is happening. CAR T cells eliminate dysfunctional B cells that drive autoimmune damage. The immune system then rebuilds itself from scratch. New healthy B cells replace the old pathogenic ones. The immune system effectively reboots itself. There is also innovation on the manufacturing side. Groups in China have shown that donor derived CAR T cells may work as an “off the shelf” version. This could reduce cost and accelerate access. If this holds true in larger trials it could be transformative for global health. My impression is that we are witnessing the emergence of a new therapeutic class that sits between cell therapy, immunology and regenerative medicine. It challenges how we design preclinical models, how we evaluate long term immune effects, how we regulate durability and how we monitor patients after immune resets. The excitement must be balanced with caution. These are small trials. There are risks. Long term immune effects are not fully known. Manufacturing complexity and toxicity remain challenges. And we need stronger mechanistic data to understand exactly why this reset works so broadly. But still. This could redefine how we treat autoimmune disease. Not symptom management. Not slow immunosuppression. But a targeted, time limited intervention that turns the system back to baseline. If the data continue to reproduce across trials, diseases once considered lifelong may become episodic and potentially reversible. A remarkable moment for clinical science. #Autoimmunity #CellTherapy #CART #Immunology #Lupus #RheumatoidArthritis #UlcerativeColitis #Innovation #TranslationalScience #Neuroscience #Biotech

How can we effectively de-target the liver upon systemic administration of LNPs ? In a new study, we show that fine-tuning the LNPs lipid composition has a vast impact on LNPs biodistribution. Herein, LNPs with high amount of DSPC show enhance colon targeting. Using interleukin-10-encoding mRNA as therapeutic cargo, these novel LNPs demonstrated a reduction of pathological burden in colitis-bearing mice. Investigating LNPs composition and lipid ratio can ultimately open new avenues for novel therapeutic modalities in different pathologies while de-targeting the liver. Congrats Riccardo, Somu, Olga, Meir, Preeti, Assaf, Lior and Dor.

Doctors told millions of people their knee cartilage was gone for good. A small molecule just proved them wrong in mice—and in human tissue. Think about that. Osteoarthritis affects roughly 20% of the U.S. population. Millions of knee and hip replacements every year. For decades, the standard answer has been: manage the pain, delay the inevitable, replace the joint. The long-held assumptions:  ↳ Once cartilage wears down, it doesn't come back  ↳ Chondrocytes lose their regenerative capacity with age  ↳ Joint replacement is the only real solution for end-stage disease  ↳ Damage is permanent What Stanford researchers found instead:  ↳ An enzyme called 15-PGDH rises in aging joints and breaks down PGE2, a molecule that supports tissue repair  ↳ Block that enzyme, and existing cartilage cells reprogram toward a younger gene-expression profile  ↳ In aged mice, the drug regrew smooth, load-bearing hyaline cartilage—not scar tissue  ↳ After ACL-type injuries, treated mice kept thicker cartilage and better movement Here's the part that stopped me: Human cartilage from end-stage joint replacements—tissue that had clinically "failed"—responded to the same treatment in the lab. It started forming new articular cartilage. Tissue we'd written off still had dormant regenerative capacity. It just needed the right signal to wake up. The path forward: An oral version of this 15-PGDH inhibitor (MF-300) has already passed Phase 1 safety testing in humans for age-related muscle weakness. The same biological axis underlies both muscle and cartilage aging. No osteoarthritis patients have been treated yet. But the door is open. The ripple effect:  1 study proves cartilage can regenerate in aged tissue  10 replications means it's real  100 patients in trials means we learn if it works in humans  At scale = millions of people might keep their original knees We spent decades accepting that worn joints only get worse. This research asks a different question: what if the cells were waiting for permission to rebuild? Follow me, Dr. Martha Boeckenfeld, for breakthroughs where science rewrites what we thought was permanent. ♻️ Share if you believe regenerative medicine deserves more attention—and more funding. Sources: Blau, H. M., & Bhutani, N. (2026, January 3). Anti-aging injection regrows knee cartilage and prevents arthritis. SciTechDaily. Singla, M., Wang, Y. X., Monti, E., Bedi, Y., Agarwal, P., Su, S., Ancel, S., Hermsmeier, M., Devisetti, N., Pandey, A., Bakooshli, M. A., Palla, A. R., Goodman, S., Blau, H. M., & Bhutani, N. (2025). Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration. Science.

Your brain produces toxic waste every minute you're awake. Most people don't know it has a cleaning system. Or that the system only turns on during deep sleep. The glymphatic system is your brain's garbage disposal. Named for the glial cells that power it. Discovered in 2012. Completely changed how we understand brain health. Every thought you think, every memory you form, every movement you make creates metabolic waste. Amyloid-beta. Tau protein. Other toxic byproducts. During the day, these accumulate between your brain cells. At night, during deep sleep, the glymphatic system flushes them out: 1. During deep sleep, brain cells shrink by 60% ↳ Creates space between neurons ↳ Allows cerebrospinal fluid to flow through ↳ Sweeps waste toward blood vessels ↳ Carries toxins out of the brain 2. The process is remarkably efficient ↳ Increases waste clearance by 10-20 fold during sleep ↳ Clears amyloid-beta that would otherwise form plaques ↳ Removes tau proteins linked to neurodegeneration ↳ Essentially "takes out the trash" every night 3. But it requires specific conditions ↳ Deep, restorative sleep (not light sleep) ↳ Side sleeping position works best ↳ Proper cerebrovascular function ↳ Adequate sleep duration Chronic sleep deprivation keeps this system from working. Less than 6 hours per night. Fragmented sleep. Sleep apnea. Chronic insomnia. The toxic proteins accumulate. Amyloid plaques form. Tau tangles develop. Neuroinflammation increases. The exact pathology we see in Alzheimer's disease. As we age, the glymphatic system becomes less efficient. Blood vessels stiffen. Fluid flow slows. Waste clearance decreases. This explains why sleep becomes more critical as you get older. And why sleep problems in midlife predict dementia 20 years later. The brutal math: One night of poor sleep increases amyloid-beta by 5% in cerebrospinal fluid. Chronic sleep debt compounds this night after night. Brain imaging shows measurable amyloid buildup after weeks of poor sleep. In otherwise healthy young adults. Who cares? I ask every dementia patient about their sleep. I commonly hear about: - years of sleeping less than 6 hours - Untreated sleep apnea - Chronic insomnia - Shift work disrupting circadian rhythms What you can do: Treat sleep apnea aggressively. CPAP adherence matters more than any dementia drug. Prioritize 7-9 hours of actual sleep time. Not just time in bed. Maintain consistent sleep-wake schedules. Even on weekends. Address insomnia with cognitive behavioral therapy before reaching for sleeping pills. Your brain needs to clean itself. Every single night. 💬 How many hours of sleep do you actually get per night? ♻️ Repost if sleep is brain maintenance, not optional 👉 Follow me (Reza Hosseini Ghomi, MD, MSE) for science-backed strategies to protect your brain health

In the 1930s, a young Black man named Vivien Thomas stepped into Vanderbilt University—not as a student or a doctor, but as a janitor. He had no medical degree, no formal training, and no title to reflect the brilliance he carried. But what he did have was unmatched talent, steady hands, and a mind that refused to settle for less. Working under Dr. Alfred Blalock, Thomas began doing far more than sweeping floors. He was soon designing and performing complex surgical experiments—quietly pioneering techniques that would one day save countless lives. Still, racism kept him in the shadows. He wore a lab coat, but his paycheck said “janitor.” When Blalock moved to Johns Hopkins in 1941, he brought Thomas with him. Together, they tackled a heartbreaking condition known as “Blue Baby Syndrome,” which caused newborns to suffer and die from lack of oxygen. Vivien was the one who cracked the code—creating a surgical technique that had never been done before. When it came time for the first human operation in 1944, Blalock stood over the patient. But it was Thomas who stood behind him—directing every move. That surgery not only saved a child’s life—it marked the beginning of modern heart surgery. For decades, his name was missing from awards, textbooks, and medical honors. But time remembered what history tried to forget. In 1976, Johns Hopkins awarded Vivien Thomas an honorary doctorate and appointed him to their faculty. The man once labeled a janitor became a legend in surgical science. Vivien Thomas didn’t just assist in heart surgery—he redefined it. His legacy is a triumph of brilliance over bias, a reminder that greatness often begins in the shadows… until the light finally finds it. #UnsungHeroes #MedicalPioneer

🚨 Major News in Gene Therapy: The U.S. FDA has approved Otarmeni, a gene therapy from Regeneron Pharmaceuticals Inc, for the treatment of a rare genetic form of hearing loss caused by mutations in the OTOF gene. Key Highlights: - First-ever gene therapy approved for genetic hearing loss - Targets otoferlin-related deafness (OTOF gene mutation) - Works by delivering a functional copy of the OTOF gene to inner ear cells - Uses a modified viral vector delivered directly into the cochlea - Addresses a rare condition affecting ~20–50 newborns per year in the U.S. Why it matters: ✔ Marks a historic first for gene therapy in sensory disorders ✔ Shifts the treatment paradigm from managing hearing loss → correcting its genetic cause ✔ Opens the door for broader applications of inner-ear and CNS gene delivery technologies ✔ Signals accelerating momentum in precision medicine for ultra-rare diseases ✔ Therapy is expected to be made available free to U.S. patients What a day for gene therapy. Certainly a significant milestone for patients, Regeneron - bringing functional hearing restoration closer to reality for children born with inherited deafness. #genetherapy #pharma #biotech #CGTweekly

A Long Island man has become the first person in New York state to be cured of sickle cell anemia. For 21 years, Sebastien Beauzile lived with the constant pain and complications of sickle cell disease, a disorder where red blood cells become crescent-shaped and clog blood vessels, causing pain, fatigue, organ damage, and a shortened life span. But at Cohen Children’s Medical Center, he received a cutting-edge therapy that’s offering new hope to thousands living with the same disease. The treatment, called Lyfgenia, works by extracting a patient’s own bone marrow stem cells, genetically modifying them in the lab, and infusing them back into the body. These altered cells then produce healthy red blood cells, reducing or even eliminating the sickling effect. For Beauzile, the transformation was profound. His chronic pain vanished. His blood began flowing freely. He could walk, travel, even dream again. “Sickle cell was like a blockade,” he said. “But now it’s just a wall I jumped over.” Sickle cell disease was first described in 1910. For over a century, patients have relied on treatments that manage symptoms but don’t cure the disease. This therapy represents something different: a one-time genetic fix that rewrites how the body makes blood. The condition primarily affects people of African, Mediterranean, and Middle Eastern descent. Doctors at Cohen Children’s hope this therapy will now reach communities long overlooked in clinical innovation. Gene therapy isn’t risk-free. It’s intensive, expensive, and still being studied in larger trials. But for the first time, a cure is within reach – not just for one patient, but potentially for many. Learn more: “Long Island man is first in New York history to be cured of sickle cell anemia.” CBS New York, 2025.

Today in @ScienceMagazine, together with my former colleagues at the Novartis Institutes for BioMedical Research, we report the discovery and characterization of first molecular glue degraders of the WIZ transcription factor (TF) for fetal hemoglobin derepression and therapeutic consideration in Sickle Cell Disease. Chemical Biologists may appreciate the CRBN-directed glue degrader library, here used in phenotypic screening of erythropoietic progenitors for HbF induction w/o effect on viability or differentiation. WIZ was discovered by proteomic study of hits and validated by CRISPR. Globin Biologists will enjoy the discovery of WIZ as a repressor of fetal hemoglobin (HbF). This biology has been intently studied, and here we find WIZ loss derepresses HbF by a local decrease in repressive H3K9me2, attributable to the association of WIZ and EHMT1/2. Medicinal chemists will appreciate the potent and selective activity of dWIZ-1 and dWIZ-2, the excellent drug-like properties, oral bioavailability and importantly the excellent tolerability in rodents and monkeys. For Biochemists, we show recruitment to CRBN as dependent on WIZ zinc finger 7, and biophysically characterize association by surface plasmon resonance. The CRBN:dWIZ: WIZ ternary complex buries 413 sq-A of surface area. Drug hunters like me might reflect on molecules that potently target a transcription factor with no pockets – effectively no tertiary structure predicted by @AlphaFold. This chemistry targets instead targets the ZnF secondary structure – truly marking the conceptual end of “undruggable” (if still in doubt). Hematologists will enjoy pharmacologic target validation in multiple pre-clinical models, a relatively selective impact on gene expression, the wide open therapeutic index, and the ease of end-game medicinal chemistry to produce investigational agents. Most importantly, for patients with Sickle Cell Disease. The advance of CRISPR-edited stem cells for transplantation, from our group and others, is a major advance. But patients need more accessible, safe, oral medicines especially in Sub-Saharan Africa. We welcome your feedback on this study, and hope dWIZ-1 and dWIZ-2 immediately prove valuable tools to the community and an inspiration for targeting disordered proteins. Finally, I thank all former colleagues in the NIBR TPD Initiative, and in particular this program’s true champion – Dr. Pamela Ting. Pam, working with you on this brave idea and on the collaborative assembly of the manuscript this last year are treasures I will always cherish, like our friendship. Article: https://lnkd.in/es6k87up Perspective: https://lnkd.in/ewn4eZNT

Breaking News in Hepatology: How Semaglutide Heals the Liver 🧬 We’ve known for a while that GLP-1 receptor agonists like semaglutide are game-changers for Metabolic Dysfunction-Associated Steatohepatitis (MASH). But a lingering question has divided the scientific community: Is the liver improving simply because the patient is losing weight, or is there something more direct at play? A groundbreaking study just published in Cell Metabolism by Drs. Maria J. Gonzalez-Rellan, and GLP1 guru Daniel Drucker, and their team provides the "smoking gun" we've been looking for. The Discovery: It’s Not Just the Weight Loss Using elegant mouse models, the researchers decoupled weight loss from drug action. They found that even when weight loss was completely removed from the equation, semaglutide still reduced liver fat, inflammation, and fibrosis. The Mechanism: The "Gatekeepers" of the Liver The study identifies a specific hero in this process: Liver Sinusoidal Endothelial Cells (LSECs). • The Missing Link: While most liver cells lack GLP-1 receptors, a specific subset of endothelial cells lining the liver's blood vessels (sinusoids) actually have them. • The Elegant Proof: When the team selectively deleted these receptors from these specific cells, the liver-protective benefits of semaglutide vanished—even if the drug was still working elsewhere in the body. • Immune Impact: The study also showed that semaglutide helps "reset" the liver's immune environment, restoring healthy T cell and B cell populations that are usually depleted by high-fat diets. Why This Matters This research shifts our understanding of GLP-1s from "weight loss drugs with side benefits" to targeted metabolic therapies. By proving that semaglutide acts directly on the liver's internal architecture, we open the door for more precise treatments for the millions living with MASH and advanced fibrosis. Huge congratulations to the team for this masterclass in molecular biology. #MASH #LiverHealth #GLP1 #Semaglutide #MedicalResearch #CellMetabolism #Hepatology #Innovation

Scientists at the Icahn School of Medicine at Mount Sinai have created a lipid nanoparticle system that enables messenger RNA (mRNA) to cross the blood-brain barrier, a major challenge in treating brain diseases. This breakthrough, published in Nature Materials, shows that the nanoparticles can effectively deliver therapeutic mRNA into the brain, offering new potential treatments for conditions like Alzheimer's, ALS, brain cancer, and drug addiction. The blood-brain barrier protects the brain from harmful substances but also blocks many beneficial therapies. In this study, the researchers designed lipid nanoparticles that take advantage of natural transport mechanisms to bypass the barrier. Their system, MK16 BLNP, proved to be more efficient at delivering mRNA compared to FDA-approved nanoparticles. In experiments using mouse models and human brain tissue, the nanoparticles successfully delivered therapeutic mRNA. This could enable the brain to produce proteins that might treat or prevent various neurological disorders, replacing missing proteins or boosting the brain’s defenses. While promising, additional studies are needed to assess long-term safety and clinical application. This new approach marks a significant step toward developing mRNA-based therapies for brain diseases, offering hope for future treatments that could tackle conditions previously difficult to address with conventional methods. #RMScienceTechInvest https://lnkd.in/dk7eYdbJ